SPI Infoamtion

1 Table of contents
1.1 List of Tables
1.2 List of Figures

2 Brain Tumor: Market Characterization
2.1 Brain Tumor Market Size
2.2 Brain Tumor Market Forecasts and Compound Annual Growth Rate
2.3 Drivers and Barriers for the Brain Tumor Market
2.3.1 Drivers for the Brain Tumor Market
2.3.2 Barriers for the Brain Tumor Market
2.4 Opportunity and Unmet Need
2.5 Key Takeaway

3 Brain Tumor Market: Competitive Assessment
3.1 Overview
3.2 Strategic Competitor Assessment
3.3 Product Profile for the Major Marketed Products in the Brain Tumor Market
3.3.1 Temodar
3.3.2 Avastin
3.3.3 Gliadel
3.4 Major Marketed Products Comparison in the Brain Tumor Market
3.5 Key Takeaway

4 Global Brain Tumor Market: Pipeline Assessment
4.1 Overview
4.2 Strategic Pipeline Assessment
4.2.1 Technology Trends Analytic Framework
4.3 Brain tumor Therapeutics –Promising Drugs under Clinical Development
4.4 Molecule Profile for Promising Drugs under Clinical Development
4.4.1 Cilengitide
4.4.2 Trabedersen
4.4.3 Neuradiab
4.4.4 XL184 (BMS-907351)
4.5 Brain Tumor Therapeutics Market – Clinical Pipeline by Mechanism of Action
4.6 Brain Tumor Pipeline – Pipeline by Clinical Phases of Development
4.6.1 Brain Tumor Therapeutics – Regulatory and Phase III Clinical Pipeline
4.6.2 Brain Tumor Therapeutics – Phase II Clinical Pipeline
4.6.3 Brain Tumor Therapeutics – Phase I Clinical Pipeline
4.6.4 Brain Tumor Therapeutics – Preclinical Pipeline
4.7 Key Takeaway

5 Global Brain Tumor Market: Implications for Future Market Competition

6 Global Brain Tumor Market: Future Players in the Brain Tumor Market
6.1 Introduction
6.2 AstraZeneca
6.2.1 Company Overview
6.2.2 Business Description
6.3 GlaxoSmithKline plc.
6.3.1 Company Overview
6.3.2 Business Description
6.4 Bristol-Myers Squibb
6.4.1 Company Overview
6.4.2 Business Description
6.5 Pfizer Inc.
6.5.1 Company Overview
6.5.2 Business Description
6.6 Eli Lilly and Company
6.6.1 Company Overview
6.6.2 Business Description
6.6.3 Oncology Portfolio
6.7 F. Hoffmann-La Roche Ltd (Roche)
6.7.1 Company Overview
6.7.2 Business Description
6.8 Novartis AG
6.8.1 Company Overview
6.8.2 Business Description
6.9 Merck & Co., Inc
6.9.1 Company Overview
6.9.2 Business Description

7 Global Brain Tumor Market: Appendix
7.1 Definitions
7.2 Acronyms
7.3 Research Methodology
7.3.1 Coverage
7.3.2 Secondary Research
7.3.3 Forecasting
7.3.4 Primary Research
7.3.5 Expert Panels
7.4 Contact Us
7.5 Disclaimer
7.6 Sources

List of Figures
Figure 1: Global Brain Tumor Therapeutics Market Forecast, 2009–2016
Figure 2: Brain Tumor Therapeutics Market – Opportunity and Unmet Need, 2010
Figure 3: Brain Tumor Therapeutics Market – Strategic Competitor Assessment, 2010
Figure 4: Technology Trends Analytic Framework of the Brain Tumor Pipeline, 2010
Figure 5: Technology Trends Analytic Framework of the Brain Tumor Pipeline – Description, 2010
Figure 6: Brain Tumor Therapeutics Market – Clinical Pipeline by Mechanism of Action, 2010
Figure 7: Brain Tumor Pipeline by Phase of Clinical Development, 2010
Figure 8: Implications for Future Market Competition in the Brain Tumor Market, 2010
Figure 9: Brain Tumor Therapeutics Market – Clinical Pipeline by Company , 2010
Figure 10: GlobalData Market Forecasting Model

List of Tables
Table 1: Global Brain Tumor Therapeutics Market Forecast, Revenue Forecasts ($m), 2009-2016
Table 2: Brain tumor Therapeutics – Most Promising Drugs Under Clinical Development, 2010
Table 3: Brain Therapeutics – Phase III Clinical Pipeline, 2010
Table 4: Brain Tumor Therapeutics – Phase II Clinical Pipeline, 2010
Table 5: Brain Tumor Therapeutics – Phase I Clinical Pipeline, 2010
Table 6: Brain Tumor Therapeutics – Preclinical Pipeline, 2010
Table 7: Bristol-Myers Squibb Company – Oncology Pipeline Products, 2010
Table 8: Bristol-Myers Squibb Company – Brain Tumor Pipeline Products, 2009
Table 9: Eli Lilly and Company – Brain Tumor Pipeline Products, 2010
Table 10: F. Hoffmann-La Roche Ltd. – Brain Tumor Pipeline Products
Table 11: Novartis AG – Brain Tumor Pipeline Products, 2010